Cite

HARVARD Citation

    Zhao, S. et al. (2019). Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Lung cancer. pp. 33-39. [Online]. 
  
Back to record